Advertisement
PRQR vs WHWK
Which Stock Would AI Choose? ProQR Therapeutics (PRQR) vs. Whitehawk Therapeutics (WHWK) Stock Comparison
Key Takeaways
- PRQR is a clinical-stage RNA-editing biotech riding fresh momentum from positive Phase 1 data and a major collaboration, while WHWK is a clinical-stage oncology company advancing a next-generation antibody drug conjugate (ADC) portfolio.
- Both companies are pre-profit and cash-burning, but their catalysts, risk profiles, and momentum profiles differ meaningfully for traders and long-term investors.
- Analyst sentiment leans positive on both names, though PRQR carries a "Strong Buy" consensus with no Hold or Sell ratings among recent coverage.
- Tickeron AI Verdict: Based on trend consistency, catalyst visibility, and relative positioning, Tickeron's AI currently favors PRQR over WHWK.
- Explore more details on PRQR Major News and PRQR Today's Price Move, as well as WHWK Major News and WHWK Today's Price Move.
- Discover Trending AI Robots to see which AI-powered trading strategies are currently in focus.
Introduction
This stock comparison examines two clinical-stage biotechnology companies operating on the Nasdaq: PRQR (ProQR Therapeutics N.V.), a Dutch developer of RNA-based therapies, and WHWK (Whitehawk Therapeutics, Inc.), an oncology company focused on antibody drug conjugates (ADCs). Both names appeal to investors comfortable with binary, catalyst-driven biotech risk, yet they occupy distinct therapeutic niches with different momentum and funding dynamics. For traders evaluating relative performance and market positioning, and for longer-horizon investors weighing pipeline depth against cash runway, understanding how these two stocks diverge is essential. The sections below review recent developments, sentiment shifts, and the factors that could shape each company's near-term trajectory.
PRQR Overview and Recent Performance
PRQR, headquartered in Leiden, the Netherlands, develops RNA (ribonucleic acid) editing therapies through its Axiomer platform, targeting severe genetic disorders. In recent weeks, the company's shares have drawn renewed attention after positive Phase 1 data for its lead candidate AX-0810, which demonstrated dose-dependent target engagement, including an up to 8-fold change in a key biomarker. This first clinical validation of the Axiomer approach was reinforced by a concurrent capital raise in which Eli Lilly participated, complementing an existing multi-billion-dollar partnership.
ProQR has also dosed the first participant in a Phase 1 trial of AX-0811 for cholestatic liver diseases and added AI-focused leadership to accelerate its pipeline. Sentiment has improved accordingly: after a prolonged decline, the stock has posted notable gains over the past one and three months, and analysts rate the name a "Strong Buy" with an average price target well above recent trading levels. Persistent losses and cash burn remain key considerations, but the improving momentum and clearer clinical catalysts have shifted the narrative in recent weeks.
WHWK Overview and Recent Performance
WHWK, formerly Aadi Bioscience, is a clinical-stage oncology company based in Morristown, New Jersey, developing next-generation antibody drug conjugates (ADCs) — engineered therapies that link antibodies to cancer-killing drugs for targeted delivery. Its three-asset ADC portfolio was in-licensed from WuXi Biologics, and the company recently expanded its programs through a new antibody development agreement with Biocytogen.
In recent weeks, Whitehawk has strengthened its balance sheet with an $87.5 million PIPE (private investment in public equity) financing that drew participation from specialist healthcare funds and insiders, extending its cash runway. The stock has delivered a strong one-year gain and positive year-to-date performance, with coverage initiated by multiple firms at Outperform or Buy ratings. However, the company remains unprofitable with meaningful cash burn, and its valuation is difficult to anchor given the absence of near-term revenue. These dynamics create a higher-risk profile balanced by a catalyst-rich ADC pipeline.
Trending AI Robots
Tickeron maintains hundreds of AI trading bots that collectively trade thousands of different tickers, each built around its own trading style, strategy, timeframe, and risk parameters. Because market conditions constantly shift, not every bot suits the current environment, which is why Tickeron curates a focused Trending AI Robots section. This page highlights the AI robots currently demonstrating the strongest alignment with prevailing market conditions, allowing traders to compare performance statistics, drawdowns, and the specific sets of tickers each robot trades. Exploring the Trending AI Robots page can help you identify strategies matched to today's tape and decide whether an automated approach fits your own trading process.
Head-to-Head Comparison
While both companies are clinical-stage biotechs, their business models and growth drivers differ sharply. PRQR is built around a platform technology (RNA editing) that could yield medicines across multiple rare and prevalent diseases, and it is anchored by a large-pharma partnership that validates the science and adds financial backing. WHWK is a more traditional oncology pipeline play focused on three specific ADC assets, with catalysts tied to clinical data readouts and potential strategic interest.
On momentum, PRQR has rebounded sharply off lows in recent months as positive data flowed, while WHWK has sustained a steadier, longer uptrend. On risk, both carry binary clinical risk and negative earnings, but PRQR's broader analyst consensus (no Hold or Sell ratings) and institutional validation contrast with WHWK's heavier reliance on a narrower set of ADC catalysts. Sector exposure also differs: genetic and rare-disease therapeutics versus oncology ADCs.
Tickeron AI Verdict
Weighing trend consistency, catalyst visibility, and relative positioning, Tickeron's AI currently leans toward PRQR over WHWK. The reasoning centers on PRQR's recent clinical validation, a uniformly positive analyst consensus, and the stabilizing influence of a major pharmaceutical partnership, which together suggest a more durable setup than WHWK's concentrated, data-dependent ADC pipeline. This assessment is probabilistic rather than definitive: both stocks remain speculative, and shifts in clinical data, financing, or broader biotech sentiment could quickly alter the relative picture.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRQR is a Hold and WHWK is a Hold.
PRQR's RSI Oscillator recovers from oversold territory
The RSI Indicator for PRQR moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 25 of the 29 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for PRQR just turned positive on October 28, 2026. Looking at past instances where PRQR's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.
Following a +3.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRQR advanced for three days, in 173 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
PRQR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PRQR as a result. In 82 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The 50-day moving average for PRQR moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRQR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for PRQR entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.397) is normal, around the industry mean (3.498). P/E Ratio (-3.375) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (9.294) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. PRQR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRQR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Momentum Indicator for WHWK turns negative, indicating new downward trend
WHWK saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned negative. In 71 of the 83 cases, the stock moved further down in the following days. The odds of a decline are at 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WHWK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for WHWK entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where WHWK's RSI Indicator exited the oversold zone, 23 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 60 cases where WHWK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for WHWK just turned positive on October 21, 2026. Looking at past instances where WHWK's MACD turned positive, the stock continued to rise in 41 of 51 cases over the following month. The odds of a continued upward trend are 80%.
Following a +6.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where WHWK advanced for three days, in 189 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
WHWK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.975) is normal, around the industry mean (3.498). P/E Ratio (-2.587) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (36.496) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. WHWK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WHWK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
PRQR | WHWK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 80 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 37 Fair valued | 31 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 78 | 63 | |
P/E GROWTH RATING 1..100 | 19 | 23 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
WHWK's Valuation (31) in the Pharmaceuticals Major industry is in the same range as PRQR (37) in the Biotechnology industry. This means that WHWK’s stock grew similarly to PRQR’s over the last 12 months.
WHWK's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as PRQR (100) in the Biotechnology industry. This means that WHWK’s stock grew similarly to PRQR’s over the last 12 months.
WHWK's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as PRQR (98) in the Biotechnology industry. This means that WHWK’s stock grew similarly to PRQR’s over the last 12 months.
WHWK's Price Growth Rating (63) in the Pharmaceuticals Major industry is in the same range as PRQR (78) in the Biotechnology industry. This means that WHWK’s stock grew similarly to PRQR’s over the last 12 months.
PRQR's P/E Growth Rating (19) in the Biotechnology industry is in the same range as WHWK (23) in the Pharmaceuticals Major industry. This means that PRQR’s stock grew similarly to WHWK’s over the last 12 months.
| PRQR | WHWK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 86% | 1 day ago 79% |
| Stochastic ODDS (%) | 1 day ago 84% | 1 day ago 77% |
| Momentum ODDS (%) | 1 day ago 85% | 1 day ago 86% |
| MACD ODDS (%) | 1 day ago 82% | 1 day ago 80% |
| TrendWeek ODDS (%) | 1 day ago 86% | 1 day ago 78% |
| TrendMonth ODDS (%) | 1 day ago 84% | 1 day ago 82% |
| Advances ODDS (%) | 3 days ago 83% | 3 days ago 78% |
| Declines ODDS (%) | 1 day ago 84% | 9 days ago 83% |
| BollingerBands ODDS (%) | 1 day ago 84% | 1 day ago 88% |
| Aroon ODDS (%) | 1 day ago 86% | 1 day ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PRQR’s FA Score shows that 1 FA rating(s) are green while WHWK’s FA Score has 2 green FA rating(s).
- PRQR’s FA Score: 1 green, 4 red.
- WHWK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PRQR’s TA Score shows that 4 TA indicator(s) are bullish while WHWK’s TA Score has 5 bullish TA indicator(s).
- PRQR’s TA Score: 4 bullish, 5 bearish.
- WHWK’s TA Score: 5 bullish, 3 bearish.
Price Growth
PRQR (@Biotechnology) experienced а -4.38% price change this week, while WHWK (@Biotechnology) price change was -0.65% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
PRQR is expected to report earnings on Nov 12, 2026.
WHWK is expected to report earnings on Mar 18, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
PRQR and
Correlation & Price change
A.I.dvisor indicates that over the last year, PRQR has been loosely correlated with FRMM. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if PRQR jumps, then FRMM could also see price increases.
| Ticker / NAME | Correlation To PRQR | 1D Price Change % | ||
|---|---|---|---|---|
| PRQR | 100% | -3.82% | ||
| FRMM - PRQR | 44% Loosely correlated | +4.61% | ||
| VIR - PRQR | 43% Loosely correlated | -0.15% | ||
| ENVB - PRQR | 43% Loosely correlated | -1.32% | ||
| WHWK - PRQR | 42% Loosely correlated | +5.19% | ||
| COYA - PRQR | 41% Loosely correlated | +1.58% | ||
More | ||||
WHWK and
Correlation & Price change
A.I.dvisor indicates that over the last year, WHWK has been loosely correlated with AXON. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if WHWK jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To WHWK | 1D Price Change % | ||
|---|---|---|---|---|
| WHWK | 100% | +5.19% | ||
| AXON - WHWK | 44% Loosely correlated | +4.26% | ||
| PRQR - WHWK | 43% Loosely correlated | -3.82% | ||
| EDIT - WHWK | 40% Loosely correlated | -4.99% | ||
| BNTC - WHWK | 40% Loosely correlated | +2.05% | ||
| LXEO - WHWK | 39% Loosely correlated | +0.33% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| KVLE | 28.38 | 0.41 | +1.46% |
| KraneShares Value Line Dynamic Dividend Equity Index ETF (KVLE) | |||
| STXG | 55.21 | 0.77 | +1.42% |
| Strive 1000 Growth ETF (STXG) | |||
| SPHD | 52.89 | 0.07 | +0.13% |
| Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) | |||
| IBMO | 25.62 | 0.02 | +0.08% |
| iShares iBonds Dec 2026 Term Muni Bond ETF (IBMO) | |||
| PCHI | 23.03 | N/A | N/A |
| Polen High Income ETF (PCHI) | |||